PLoS ONE (Jan 2019)

Engineering a single-chain antibody against Trypanosoma cruzi metacyclic trypomastigotes to block cell invasion.

  • Lara Maria Kalempa Demeu,
  • Rodrigo Jahn Soares,
  • Juliana Severo Miranda,
  • Lisandro A Pacheco-Lugo,
  • Kelin Gonçalves Oliveira,
  • Cristian Andrés Cortez Plaza,
  • Philippe Billiald,
  • Juliana Ferreira de Moura,
  • Nobuko Yoshida,
  • Larissa Magalhães Alvarenga,
  • Wanderson Duarte DaRocha

DOI
https://doi.org/10.1371/journal.pone.0223773
Journal volume & issue
Vol. 14, no. 10
p. e0223773

Abstract

Read online

Trypanosoma cruzi is a flagellate protozoan pathogen that causes Chagas disease. Currently there is no preventive treatment and the efficiency of the two drugs available is limited to the acute phase. Therefore, there is an unmet need for innovative tools to block transmission in endemic areas. In this study, we engineered a novel recombinant molecule able to adhere to the T. cruzi surface, termed scFv-10D8, that consists of a single-chain variable fragment (scFv) derived from mAb-10D8 that targets gp35/50. The synthetic gene encoding scFv-10D8 was cloned and fused to a 6×His tag and expressed in a prokaryotic expression system. Total periplasmic or 6xHis tag affinity-purified fractions of scFv-10D8 retained the capacity to bind to gp35/50, as shown by Western blot analyses. Pre-incubation of metacyclic trypomastigotes with scFv-10D8 showed a remarkable reduction in cell invasion capacity. Our results suggest that scFv-10D8 can be used in a paratransgenic approach to target parasites in insect vectors, avoiding dissemination of infective forms. Such advances in the development of this functional molecule will surely prompt the improvement of alternative strategies to control Chagas disease by targeting mammalian host stages.